Bristol-Myers Squibb Co
BMV:BMY
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
789
1 261
|
| Price Target |
|
We'll email you a reminder when the closing price reaches MXN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Profitability Summary
Bristol-Myers Squibb Co's profitability score is 60/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
Score
Margins
Earnings Waterfall
Bristol-Myers Squibb Co
Margins Comparison
Bristol-Myers Squibb Co Competitors
| Country | Company | Market Cap |
Gross Margin |
Operating Margin |
Net Margin |
||
|---|---|---|---|---|---|---|---|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
112.5B USD |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.8B USD |
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.8B GBP |
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222.2B CHF |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
155.1B USD |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.2B USD |
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.5B AUD |
Loading...
|
Loading...
|
Loading...
|
Return on Capital
Return on Capital Comparison
Bristol-Myers Squibb Co Competitors
| Country | Company | Market Cap | ROE | ROA | ROCE | ROIC | ||
|---|---|---|---|---|---|---|---|---|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
112.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.8B GBP |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222.2B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
155.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.5B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|